IP
RXRX icon

Indivisible Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Indivisible Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
+65,000
New +$216K 0.01% 571

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Indivisible Partners's RXRX Position: Q2 2026 in Review

Indivisible Partners opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 65,000 shares worth $239K. The stake represents 0.01% of the portfolio and ranks #571 among its holdings.

341 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Indivisible Partners held 65,000 shares of Recursion Pharmaceuticals worth $239K as of Q2 2026.
  • Recursion Pharmaceuticals was a new Indivisible Partners position in Q2 2026.
  • Recursion Pharmaceuticals made up 0.01% of Indivisible Partners's portfolio in Q2 2026, its #571 holding.
  • 341 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Indivisible Partners's 13F filing for Q2 2026, filed 4 Aug 2026.